Alessio Cortellini
Overview
Explore the profile of Alessio Cortellini including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
211
Citations
3640
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nassar A, Abou Alaiwi S, El Zarif T, Denu R, Macaron W, Abdel-Wahab N, et al.
J Immunother Cancer
. 2025 Mar;
13(3).
PMID: 40032601
Background: Data on the safety profiles and clinical outcomes of patients with solid tumors and cardiac metastasis treated with immune checkpoint inhibitors (ICIs) are limited. Methods: This is an international...
2.
Barrichello A, Elkrief A, Ricciuti B, Ganta T, Marron T, Wang X, et al.
Clin Lung Cancer
. 2025 Feb;
PMID: 40021433
Background: Non-small cell lung cancer (NSCLC) patients aged ≥80 years [y] are underrepresented in clinical trials. We evaluated whether age correlates with a distinct immunophenotype or impacts outcomes to first-line...
3.
Pecci F, Cognigni V, Giudice G, Paoloni F, Cantini L, Saini K, et al.
Crit Rev Oncol Hematol
. 2025 Feb;
209:104654.
PMID: 39923921
Cholesterol and its metabolism seem to be involved not only in cancer progression but also in immune cells activity. In this comprehensive review, we summarize preclinical, translational, and clinical evidence...
4.
Cortellini A, Brunetti L, Di Fazio G, Garbo E, Pinato D, Naidoo J, et al.
J Immunother Cancer
. 2025 Feb;
13(2).
PMID: 39904562
Background: Pembrolizumab monotherapy is an established front-line treatment for advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) tumor proportion score (TPS)≥50%. However, real-world data on its...
5.
Wu M, Fulgenzi C, DAlessio A, Cortellini A, Celsa C, Manfredi G, et al.
JHEP Rep
. 2025 Jan;
7(2):101232.
PMID: 39877031
Background & Aims: Atezolizumab/bevacizumab (A/B) is now a standard first-line treatment for advanced hepatocellular carcinoma (HCC), but the optimal second-line regimen is not known. We evaluated real-world treatment patterns and...
6.
Lucchetti J, Angotti L, Parisi A, Basso M, Polito M, Zoratto F, et al.
Clin Colorectal Cancer
. 2025 Jan;
PMID: 39856001
Background: Both aflibercept and bevacizumab-based regimens are available II-line treatment options for patients with metastatic colorectal cancer (mCRC). However, no head-to-head trials established the optimal anti-angiogenic strategy for this setting....
7.
Rakaee M, Tafavvoghi M, Ricciuti B, Alessi J, Cortellini A, Citarella F, et al.
JAMA Oncol
. 2024 Dec;
11(2):109-118.
PMID: 39724105
Importance: Only a small fraction of patients with advanced non-small cell lung cancer (NSCLC) respond to immune checkpoint inhibitor (ICI) treatment. For optimal personalized NSCLC care, it is imperative to...
8.
Ghidini M, Hahne J, Hahne J, Senti C, Heide T, Proszek P, et al.
Clin Cancer Res
. 2024 Dec;
31(4):707-718.
PMID: 39688961
Purpose: We tested whether circulating tumor DNA (ctDNA) changes may be used to assess early response and clinical outcomes in patients with metastatic colorectal cancer (mCRC) undergoing first-line systemic anticancer...
9.
Priantti J, Fujiwara Y, de Moraes F, Michelon I, Castro C, Leighl N, et al.
JCO Precis Oncol
. 2024 Nov;
8:e2400331.
PMID: 39576954
Purpose: The activity of osimertinib is not fully characterized in non-small-cell lung cancer (NSCLC) with uncommon epidermal growth factor receptor () mutations. Therefore, we conducted a systematic review and meta-analysis...
10.
Takada K, Takamori S, Shimokawa M, Pinato D, Cortellini A
Int J Cancer
. 2024 Nov;
156(5):914-919.
PMID: 39501485
The potential impact of concomitant medications such as systemic antibiotics, proton pump inhibitors (PPIs), and probiotics in patients with extensive-stage small cell lung cancer (ES-SCLC) receiving first-line chemo-immunotherapy combinations remains...